Health care, globally, is struggling to provide equitable access to treatment, improve outcomes and contain costs.
As a Primary Care Physician, you are responsible for addressing medical needs of patients, including the growing geriatric population and patients with comorbidities.
Managing primary care practice in today’s clinical setting is challenging. One in four primary care patients in North America is prescribed at least one medication that commonly causes adverse drug reactions due to genetic variability in drug metabolism. At CQuentia, we understand that identifying potential adverse drug events prior to their onset and prescribing medications appropriate for the patient’s physiology is a critical determinant of your clinical success.
Find out what other leading institutions are saying about CQuentia.
The field of Pharmacogenomics (PGx) has evolved to help providers address the current “one size fits all” method of prescribing medications. CQuentia’s industry-leading Pharmacogenomic (PGx) Testing Program will streamline your general practice program and significantly reduce risk by providing the advanced clinical insight of the patient’s unique genetic profile to help prescribe medications that maximizes benefits and minimizes patient risk. PGx-guided medication management will not only help manage patients’ comorbidities, but its application expands through the continuum of care by reducing narcotic use during surgery, decreasing instances of post-operative side effects (such as nausea/vomiting) and improving post-operative pain.
Our comprehensive PGx panel, developed incorporating the guidelines laid by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in our CLIA-certified laboratory, further identifies a patient’s risk of malignant hyperthermia or thrombotic risk during hospitalization. Combining medication efficacy with genetic factors will provide you with a greater level of patient detail that is needed to deliver Precision Medicine.
CQuentia, more than a lab, more than a test. The leaders in the new frontier of genomics testing and personalized medicine.